Capital Advantage Inc. Purchases New Holdings in Johnson & Johnson (NYSE:JNJ)

Capital Advantage Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,910 shares of the company's stock, valued at approximately $710,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. IFS Advisors LLC boosted its position in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson in the fourth quarter worth about $32,000. Finally, Conquis Financial LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $33,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $171.82.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $2.76 during trading on Wednesday, reaching $157.23. 7,853,057 shares of the company's stock traded hands, compared to its average volume of 7,892,091. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $378.31 billion, a P/E ratio of 23.64, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm's 50-day moving average is $158.35 and its 200 day moving average is $154.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.